Conduit Pharmaceuticals Inc

Conduit Pharmaceuticals, Inc. is a multi-asset clinical-stage, life science company. The Company facilitates the development and commercialization of clinical assets. The Company acquires and funds the development of Phase 2-ready assets, builds an integrated and advanced platform-driven approach powered by artificial intelligence (AI) and cybernetics, and seeks exit through third-party license deals following successful clinical trials. The Company’s asset pipeline includes AZD1656 (a Glucokinase Activator), AZD5658 (Glucokinase Activator), and AZD5904 (a Myeloperoxidase Inhibitor). AZD1656 is a glucokinase activator used in diabetes mellitus. It is used as a treatment option for Hashimoto’s Thyroiditis. AZD5904 includes a potent, irreversible inhibitor of human myeloperoxidase (MPO), for the treatment, prevention, and prophylaxis of idiopathic male infertility.